Sarah McCrary, APRN
Gerontology · Greenville, TXNPI 1740896539
Payments from drug & device makers
Across 108 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$323
- AbbVie$246
- Axsome Therapeutics, Inc.$212
- Pfizer$190
- Lilly USA, LLC$176
- AstraZeneca$140
- plus $732 from 23 others
What the payments were for
- Food & beverage$2,019100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 17 | $323 |
| AbbVie | 11 | $246 |
| Axsome Therapeutics, Inc. | 11 | $212 |
| Pfizer | 9 | $190 |
| Lilly USA, LLC | 10 | $176 |
| AstraZeneca | 8 | $140 |
| Astellas Pharma US Inc | 5 | $91 |
| Idorsia Pharmaceuticals US Inc | 4 | $63 |
| Boehringer Ingelheim | 4 | $63 |
| Johnson & Johnson | 4 | $56 |
| Exact Sciences | 3 | $45 |
| Novo Nordisk | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $35 |
| GSK | 2 | $35 |
| Mylan Specialty L.p. | 2 | $33 |
| Eisai Inc. | 1 | $33 |
| Vanda Pharmaceuticals Inc. | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Cardiovascular Systems Inc. | 1 | $22 |
| Acadia Pharmaceuticals Inc | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Novartis | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Bayer | 1 | $18 |
| Corcept Therapeutics | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Clarus Therapeutics Inc. | 1 | $14 |
| Philips North America LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$120
How this compares
$2,019 in reported general payments places this provider in the 80th percentile of 653 gerontology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 71 | $69,888 |
| EliquisApixaban | 65 | $59,621 |
| MounjaroTirzepatide | 39 | $58,064 |
| FarxigaDapagliflozin Propanediol | 44 | $25,685 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $17,055 |
| JardianceEmpagliflozin | 12 | $13,591 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 14 | $12,914 |
| MyrbetriqMirabegron | 13 | $8,619 |
| Spiriva RespimatTiotropium Bromide | 12 | $7,429 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $7,150 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $5,258 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 19 | $4,237 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 25 | $4,045 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 11 | $3,474 |
| Omeprazole | 173 | $3,100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $37 | $69,88871 claims |
| PfizerEliquis | $190 | $59,62165 claims |
| Lilly USA, LLCMounjaro | $176 | $58,06439 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Arexvy | $35 | $31,91671 claims |
| AstraZenecaFarxiga, Symbicort | $140 | $30,94355 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $63 | $21,02024 claims |
| Astellas Pharma US IncMyrbetriq | $91 | $8,61913 claims |
| AbbVieSynthroid | $246 | $78916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 653 gerontology providers in Texas.
Other gerontology in Greenville
- Kimberly WelchCoppell$113K
- Tiffany KesslerDallas$84K
- Jennifer WestFort Worth$67K
- Meagan ChavarriaHouston$40K
- Bailey EstesAbilene$34K
- Scott ZelaHouston$28K
- Marissa Marti-SmithDallas$27K
- Andrew BargerAustin$22K
- Samantha BoggsGalveston$15K
- Amber ArmstrongAustin$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.